The New Paper

September 23, 2020

Johnson & Johnson enters Phase 3 coronavirus vaccine trials

Johnson & Johnson announced the launch of Phase 3 trials for its coronavirus vaccine candidate, becoming the fourth company to enter late-stage trials in the US. J&J’s vaccine is notably expected to require only one dose, compared to other vaccines currently in development (by companies including Moderna and Pfizer) that could require two doses.

Extra: Here’s a tracker of vaccines and treatments currently in development.

This story is from the September 23, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.